Author

J. A. Fraietta

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

C. H. June· 2 shared A. Chew· 1 shared A. DeVine· 1 shared A. M. Fuller· 1 shared A. Satpathy· 1 shared A. Weeraratna· 1 shared B. Hwang· 1 shared B. L. Levine· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

C. H. June

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Armored Bicistronic CAR T Cells with Dominant-negative TGF-β Receptor II to Overcome Resistance in Glioblastoma.

N. Li, J. L. Rodriguez, Y. Yin, M. T. Logun, S. Yu, K. A. Hicks, V. Zhang, L. Zhang, C. Xie, J. Wang, J. A. Fraietta, Z. A. Binder, Z. Lin, D. M. O'Rourke

This paper develops a tri-modular CAR T cell construct with a dominant-negative TGF-β receptor II to overcome GBM resistance by enhancing T cell function and efficacy in a preclinical model.

bioRxiv · Feb 26, 2024Cancer Biology

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells

C. A. Tsuchida, N. Brandes, R. Bueno, M. Trinidad, T. Mazumder, B. Yu, B. Hwang, C. Chang, J. Liu, Y. Sun, C. R. Hopkins, K. R. Parker, Y. Qi, A. Satpathy, E. Stadtmauer, , J. A. Doudna

This study investigates chromosome loss in CRISPR-Cas9-engineered T cells and shows a modified manufacturing process reduces it while preserving editing efficacy.

bioRxiv · Mar 22, 2023Cell Biology

Oncogene-induced matrix reorganization controls CD8+ T cell function in the soft-tissue sarcoma microenvironment

A. M. Fuller, H. C. Pruitt, Y. Liu, V. M. Irizarry-Negron, H. Pan, H. Song, A. DeVine, R. S. Katti, S. Devalaraja, G. E. Ciotti, M. Gonzalez, E. F. Williams, I. Murazzi, D. Ntekoumes, N. Skuli, , T. S. K. Eisinger-Mathason

This study identifies YAP1-driven collagen VI deposition in sarcoma as a mechanism suppressing CD8+ T cell function through ECM remodeling and autophagy inhibition.

bioRxiv · Mar 31, 2022Cancer Biology

Decade-long remissions of leukemia sustained by the persistence of activated CD4+ CAR T-cells

J. J. Melenhorst, G. M. Chen, M. Wang, D. . L. Porter, P. Gao, S. Bandyopadhyay, I. Pruteanu-Malinici, C. L. Nobles, S. Maji, N. V. Frey, S. I. Gill, L. Tian, I. Kulikovskaya, M. Gupta, M. M. Davis, , C. H. June

This study tracks long-term persistence of CD4+ CAR T-cells in CLL patients, showing their role in sustained remission and clonal stability over 10 years.

bioRxiv · May 7, 2021 · PreprintImmunology